// Biotech and Pharma Therapeutics
Piedmont Healthcare uses predictive analytics to improve BP medication adherence
March 5, 2025 / Predictive Analytics / Healthcare / Hypertension / Population Health Management / Elecronic Health Records Integration / Data Driven Patient Interventions
Piedmont Healthcare uses predictive analytics and prescription fill data to identify at-risk patients and improve hypertension medication adherence. This approach enhances patient outcomes, reduces intervention waste, and supports value-based care through early, data-driven interventions.
Healthcare’s Workforce Blueprint is Out Of Date. It’s Time For A Change
March 5, 2025 / Nursing Workforce Resilience / Healthcare Staffing Solutions / Hospital Workforce Management
Healthcare’s outdated workforce strategies hinder nurse retention and resilience. Hospitals must embrace flexible staffing models, technology-driven scheduling, and mentorship programs to meet generational workforce needs, enhance work-life balance, and address ongoing nursing shortages. Adaptation is essential for long-term workforce stability.
Cancellation of NIH summer internships disrupts ‘vital’ training program for U.S. scientists
March 5, 2025 / NIH Internship Cancellation / Biomedical Research Training / STEM Workforce Dvelopment / Science Education Funding Cuts
The NIH’s cancellation of its long-running summer internship program disrupts hands-on biomedical training for aspiring scientists. The loss of this opportunity, alongside NSF research cuts, threatens workforce development and diversity in U.S. scientific research.
NZ Health’s poor data back-end safeguards flagged
March 4, 2025 / New Zealand Health Data Privacy / Te Whatu Ora Data Scurity / Vaccine Data Breach / Electronic Health Records Security
New Zealand’s Ministry of Health and Te Whatu Ora lacked adequate safeguards for personal health data shared with third-party providers. An inquiry found compliance gaps in data protection, prompting revisions to information-sharing agreements and stricter oversight measures.
One Year Post-Change Healthcare Cyber Attack: What Keeps This Healthcare CTO Awake at Night
March 4, 2024 / Change Healthcare Cyberattack / Healthcare Data Security / Ransomware Threats
The 2024 Change Healthcare cyberattack exposed vulnerabilities in healthcare data security, affecting 190 million Americans. In response, organizations are strengthening cybersecurity frameworks, improving incident response, enhancing vendor risk management, and increasing employee training to safeguard sensitive patient data.
// 4th Industrial Revolution
The Role of Biomechanics in Designing High-Performance Spinal Implants
March 5, 2025 / Biomechanics / Spinal Implants / Spinal Fusion Technology / Innovasis
Innovasis integrates biomechanics into spinal implant design to enhance patient outcomes. By using bioactive coatings, advanced materials, and region-specific customization, these implants promote spinal fusion, restore function, and improve support while minimizing complications.
The Role of Telehealth in Managing Chronic Illness Before Complications Arise
March 5, 2025 / Telehealth / Chronic Disease / Remote Patient Monitoring / Virtual Healthcare Access / Digital Health Solutions
Telehealth enhances chronic disease management by enabling remote monitoring, early intervention, and improved patient-provider communication. Despite barriers like digital access and privacy concerns, its integration with traditional care is expanding, reducing complications and improving long-term health outcomes.
CMO: Provider organizations should deploy AI where it solves real pain points
March 5, 2025 / AI in Healthcare IT / Clinical Decision Support AI / Medication Adherence Technology / Prior Authorization Automation
AI in healthcare should address real challenges, such as automating prior authorizations, improving medication adherence, and enhancing clinical decision support. Prioritizing interoperability and patient engagement will reduce administrative burdens, improve collaboration, and drive better outcomes.
Unlocking AI’s Potential in Healthcare — A Semantic Foundation
March 5, 2025 / AI in Healthcare / Data Management / Sematic AI / AI-driven Clinical Insights / Secure AI
AI’s potential in healthcare depends on high-quality, well-structured data. A semantic approach, using knowledge graphs and contextualization, enhances AI’s accuracy, compliance, and security. This ensures AI-driven insights are reliable, scalable, and transformative for patient care.
NextGen taking a new look at EHRs through the eyes of AI
March 4, 2025 / NextGen Healthcare / Clinical Workflows / Intelligent EHR Systems / Healthcare Automation Technology
NextGen Healthcare is reimagining EHRs with AI-driven “”agentification”” to enhance clinical workflows, automate tasks, and improve provider experiences. Thoughtful AI integration can reduce administrative burdens, optimize patient care, and reshape healthcare IT for better efficiency.
// Business & Markets
Apollo Hospitals enters new collaboration to augment cardiovascular care
March 5, 2025 / AI in Cardiovascular Care / Apollo Hospitals / Healthcare Data Analytics
Apollo Hospitals is partnering with Solventum to enhance its AI-driven cardiovascular disease risk prediction tool. By integrating predictive analytics and patient classification methodologies, the collaboration aims to improve patient outcomes, optimize resource use, and expand access to cardiovascular care.
Medisafe and EMD Serono Partner to Launch Global HIV Resource Center
March 5, 2025 / Medisafe / EMD Serono / Partnership / Digital Health / HIV Care / Proactive Health Monitoring
Medisafe and EMD Serono have launched the HIV Resource Center to improve medication adherence, provide personalized support, enable proactive health monitoring, and enhance patient education. This digital platform empowers individuals to manage HIV treatment effectively and improve outcomes.
Bicycle Health, Wellpath Ink Additional OUD Treatment Contract with Federal Bureau of Prisons
March 5, 2025 / Virtual Opioid Use Disorder Treatment / OUD Care / Formaly Incarcerated Individuals / Telehealth Addiction Treatment / Reentry Programs
Bicycle Health and Wellpath expanded their partnership with the Federal Bureau of Prisons to provide virtual opioid use disorder (OUD) treatment for individuals transitioning from incarceration. The program improves access to medication, therapy, and peer support, reducing relapse and overdose risks.
With patent losses on the horizon, Amgen refocuses its business strategy
March 5, 2025 / Amgen / Biosimilars Expansion / BiTE Cancer Therapy Innovation / Drug Development / Amgen / Rare Disease Drug Development
Facing upcoming patent losses, Amgen is expanding its biosimilar portfolio, investing in oncology, inflammation, cardiovascular, and rare diseases, and developing innovative therapies like BiTEs and obesity treatments. The company aims for sustained growth through acquisitions and R&D advancements.
Acelyrin rebuffs Concentra bid, believing Alumis option better
March 5, 2025 / Acelyrin Alumis Merger / Immunology Biopharma Acquisition / Lonigutamab Immune Therapy / Drug Development
Acelyrin rejected Concentra’s takeover bid, favoring its planned merger with Alumis to form a late-stage biopharma focused on immune-mediated diseases. The merger follows Acelyrin’s strategic shift after the failure of its lead candidate, izokibep, in a uveitis trial.
// Legal & Regulatory
FDA puts clinical hold on BioNTech’s malaria vaccine trial
March 5, 2025 / BioNTech / Malaria Vaccine Trial / FDA Clinical Hold / mRNA Vaccine / Vaccine Development
The FDA has placed a clinical hold on BioNTech’s Phase I/II malaria vaccine trial, requiring unspecified changes. BioNTech is addressing the FDA’s concerns while continuing efforts to develop mRNA-based malaria vaccines amid competition from GSK and Shanghai Fosun.
DOGE claims $30M savings from canceling 30 FDA leases
March 4, 2025 / FDA Facility Closures / Drug Testing Lab Shutdowns / Government Healthcare Budget Cuts / FDA Regulatory Oversight Risks
The Department of Government Efficiency canceled 30 FDA facility leases, claiming nearly $30M in savings. Experts warn closures, particularly the St. Louis drug testing lab, may compromise drug safety oversight, increasing risks to public health and regulatory effectiveness.
Gilead sets aside $200M for potential settlement over HIV drug speaker program
March 4, 2025 / Gilead Sciences / Novartis / HIV Drug Settlement / Physician Payment Transparency / Physician Payment Sunshine Act
Gilead Sciences has allocated $200M for a potential settlement over a government investigation into its HIV drug speaker programs. This follows increased scrutiny of pharmaceutical payments to healthcare providers and previous settlements by Novartis and Teva for similar allegations.
FDA Files Corcept’s New Drug Application for Relacorilant as Treatment for Patients With Hypercortisolism
March 3, 2025 / Relacorilant FDA Approval / Cushing’s Syndrome / Cortisol Modulator Therapy / Hypercortisolism Clinical Trials / Drug Development
The FDA has accepted Corcept Therapeutics’ New Drug Application for relacorilant, a selective cortisol modulator for treating endogenous hypercortisolism (Cushing’s syndrome). Backed by positive clinical trial results, relacorilant may become a new standard of care.
Genevant and Arbutus initiate patent lawsuit against Moderna
March 4, 2025 / Moderna LNP Patent Lawsuit / Genevant Arbutus / Moderna / mRNA Vaccine / Patent Litigation / Spikevax Intellectual Property Case
Genevant Sciences and Arbutus Biopharma have filed international lawsuits against Moderna, alleging patent infringement on their lipid nanoparticle (LNP) technology used in Spikevax and other products. The legal actions seek monetary damages and injunctions ahead of a 2025 U.S. trial.
// Research & Development
Amgen enters Maritime, launching 2 late-stage obesity trials for MariTide
March 5, 2025 / Amgen / MariTide / Obesity Trials / GLP-1 Weight Loss Drug Research / Clinical Trials
Amgen has launched two Phase 3 trials for its obesity drug MariTide, testing its impact on weight loss in individuals with and without Type 2 diabetes. The program follows promising Phase 2 data showing up to 20% weight loss without plateau.
‘Simply good science’: Women’s health research reveals clues to aging and Alzheimer’s
March 5, 2025 / Women’s Health / Hormones and Alzheimer’s Risk / Biomedical Research Funding Cuts
A Science Advances special issue highlights new research on women’s health, emphasizing links between hormones, chromosomes, aging, and Alzheimer’s. The issue underscores the importance of studying sex differences in biomedical research amid funding and policy challenges.
PepGen pauses Phase II DMD trial to review safety data
March 5, 2025 / PepGen DMD Clinical Trial / Duchenne Muscular Dystrophy Treatment / FDA Orphan Drug Designation / Gene Therapy Research
PepGen has paused its Phase II CONNECT2-EDO51 trial for Duchenne muscular dystrophy (DMD) to review safety data from an ongoing Phase II study. The company aims to assess PGN-EDO51’s impact on dystrophin levels before proceeding with further trials.
Pliant halts lung fibrosis trial amid safety concerns
March 5, 2025 / Pliant Therapeutics / IPF Trial / Bexotegrast Lung Fibrosis Treatment / Clinical Trial Safety Concerns
Pliant Therapeutics has halted its Phase IIb Beacon-IPF trial for bexotegrast in idiopathic pulmonary fibrosis (IPF) due to increased adverse events in the treatment group. The decision led to a significant drop in the company’s stock value.
SECuRE trial pre-chemo participants experience PSA level drops
March 5, 2025 / SECuRE Trial Prostate Cancer / PSA Reduction / Clinical Trials
The SECuRE trial for 67Cu-SAR-bisPSMA in prostate cancer has advanced to Phase 2 after showing significant PSA reductions, especially in pre-chemotherapy patients. The treatment demonstrated a favorable safety profile, prompting expanded enrollment and combination therapy exploration.
// Politics
US judge blocks Trump administration from cutting NIH grants amid ongoing litigation
March 5, 2025 / NIH / Trump / Lawsuit / Biomedical Research Funding Lawsuit
A federal judge blocked the Trump administration’s attempt to cut NIH grants, citing ongoing litigation. Medical and academic organizations argue the cuts would harm biomedical research. The ruling ensures continued NIH funding while lawsuits challenging the reductions proceed.
Trump administration policies could create headwinds across healthcare: Fitch
March 5, 2025 / Trump Healthcare Policy Impact / Medicaid Funding Cuts / FDA Staff Reduction / Trump / Fitch Healthcare
Fitch Ratings warns that Trump administration policies, including Medicaid cuts and FDA staff reductions, could negatively impact healthcare companies. Potential consequences include increased uninsured rates, delayed drug approvals, and industry-wide financial pressures, prompting possible M&A activity.
NIH nominee is ‘convinced’ vaccines don’t cause autism, but won’t rule out more studies on the issue
March 5, 2025 / Jay Bhattacharya / NIH Nomination / Vaccine Autism Debate / MMR Vaccine Safety Studies / RFK Jr. Vaccine Policy
NIH nominee Jay Bhattacharya stated he is convinced vaccines do not cause autism but did not rule out further studies. His stance contrasts with Health Secretary RFK Jr.’s views, raising concerns amid a growing measles outbreak in Texas.
Russian trade groups call on govt to postpone discriminatory procurement rules
March 5, 2025 / Russia Pharmaceutical Procurement Rules / Drug Shortages in Russia / EAEU Drug Market Regulations
Russian pharmaceutical groups are urging the government to delay procurement rules favoring domestically produced drugs, warning of potential shortages and price increases. They seek postponement until 2027 to allow time for localization and supply chain adjustments.
Pfizer CEO says he’s prepared to shift manufacturing to the U.S. amid tariff threats
March 3, 2025 / Pfizer US Manufacturing Shift / Trump Pharmaceutical Tariffs / Drug Production / Global Drug Supply Chain Impact
Pfizer CEO Albert Bourla stated the company could shift some overseas manufacturing to U.S. facilities if Trump’s proposed pharmaceutical tariffs take effect. The industry is engaging with the administration to navigate policy changes impacting global drug production and supply chains.